Non-invasive assessment of inter-and intrapatient variability of integrin expression in metastasized prostate cancer by PET
Standard
Non-invasive assessment of inter-and intrapatient variability of integrin expression in metastasized prostate cancer by PET. / Beer, A. J.; Schwarzenbock, S. M.; Zantl, N.; Souvatzoglou, M.; Maurer, T.; Watzlowik, P.; Kessler, H.; Wester, H. J.; Schwaiger, M.; Krause, B. J.
In: ONCOTARGET, Vol. 7, No. 19, 10.05.2016, p. 28151-28159.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Non-invasive assessment of inter-and intrapatient variability of integrin expression in metastasized prostate cancer by PET
AU - Beer, A. J.
AU - Schwarzenbock, S. M.
AU - Zantl, N.
AU - Souvatzoglou, M.
AU - Maurer, T.
AU - Watzlowik, P.
AU - Kessler, H.
AU - Wester, H. J.
AU - Schwaiger, M.
AU - Krause, B. J.
N1 - 1949-2553 Beer, Ambros J Schwarzenbock, Sarah M Zantl, Niko Souvatzoglou, Michael Maurer, Tobias Watzlowik, Petra Kessler, Horst Wester, Hans-Jurgen Schwaiger, Markus Krause, Bernd Joachim Journal Article United States Oncotarget. 2016 May 10;7(19):28151-9. doi: 10.18632/oncotarget.8611.
PY - 2016/5/10
Y1 - 2016/5/10
N2 - PURPOSE: Due to the high expression of the integrin αvβ3 not only on endothelial cells, but also on mature osteoclasts and prostate cancer cells, imaging of osseous metastases with αvβ3-targeted tracers seems promising. However, little is known about the patterns of αvβ3-expression in metastasized prostate cancer lesions in-vivo. Thus we evaluated the uptake of the αvβ3-specific PET tracer [18F]Galacto-RGD for assessment of bone metastases in prostate cancer patients.RESULTS: [18F]Galacto-RGD PET identified 58/74 bone-lesions (detection rate of 78.4%) and lymph node metastases in 2/5 patients. The SUVmean was 2.12+/-0.94 (range 0.70-4.38; tumor/blood 1.36+/-0.53; tumor/muscle 2.82+/-1.31) in bone-lesions and 2.21+/-1.18 (range 0.75-3.56) in lymph node metastases. Good visualization and detection of bone metastases was feasible due to a low background activity of the surrounding normal bone tissue.METHODS: 12 patients with known metastasized prostate cancer according to conventional staging (including bone-scintigraphy and contrast-enhanced CT; median PSA 68.63 ng/ml, range 3.72-1935) were examined with PET after i.v.-injection of [18F]Galacto-RGD. Two blinded nuclear-medicine physicians evaluated the PET-scans in consensus concerning lesion detectability. Volumes-of-interest were drawn in the PET-scans over all metastases defined by conventional staging (maximum of 11 lesions/patient), over the left ventricle, liver and muscle and standardized-uptake-values (SUVs) were calculated.CONCLUSIONS: Our data show generally elevated uptake of [18F]Galacto-RGD in bone metastases from prostate cancer with a marked inter- and intrapatient variability. While [18F]Galacto-RGD PET is inferior to bone scintigraphy for detection of osseous metastases, it might be valuable in patient screening and monitoring of αvβ3-targeted therapies due to the high variability of αvβ3-expression.
AB - PURPOSE: Due to the high expression of the integrin αvβ3 not only on endothelial cells, but also on mature osteoclasts and prostate cancer cells, imaging of osseous metastases with αvβ3-targeted tracers seems promising. However, little is known about the patterns of αvβ3-expression in metastasized prostate cancer lesions in-vivo. Thus we evaluated the uptake of the αvβ3-specific PET tracer [18F]Galacto-RGD for assessment of bone metastases in prostate cancer patients.RESULTS: [18F]Galacto-RGD PET identified 58/74 bone-lesions (detection rate of 78.4%) and lymph node metastases in 2/5 patients. The SUVmean was 2.12+/-0.94 (range 0.70-4.38; tumor/blood 1.36+/-0.53; tumor/muscle 2.82+/-1.31) in bone-lesions and 2.21+/-1.18 (range 0.75-3.56) in lymph node metastases. Good visualization and detection of bone metastases was feasible due to a low background activity of the surrounding normal bone tissue.METHODS: 12 patients with known metastasized prostate cancer according to conventional staging (including bone-scintigraphy and contrast-enhanced CT; median PSA 68.63 ng/ml, range 3.72-1935) were examined with PET after i.v.-injection of [18F]Galacto-RGD. Two blinded nuclear-medicine physicians evaluated the PET-scans in consensus concerning lesion detectability. Volumes-of-interest were drawn in the PET-scans over all metastases defined by conventional staging (maximum of 11 lesions/patient), over the left ventricle, liver and muscle and standardized-uptake-values (SUVs) were calculated.CONCLUSIONS: Our data show generally elevated uptake of [18F]Galacto-RGD in bone metastases from prostate cancer with a marked inter- and intrapatient variability. While [18F]Galacto-RGD PET is inferior to bone scintigraphy for detection of osseous metastases, it might be valuable in patient screening and monitoring of αvβ3-targeted therapies due to the high variability of αvβ3-expression.
KW - Aged Aged, 80 and over Bone Neoplasms/diagnostic imaging/secondary Humans Image Interpretation, Computer-Assisted Integrin alphaVbeta3/analysis Male Middle Aged Peptides, Cyclic Positron-Emission Tomography/methods Prostatic Neoplasms/diagnostic imaging/p
U2 - 10.18632/oncotarget.8611
DO - 10.18632/oncotarget.8611
M3 - SCORING: Journal article
C2 - 27058620
VL - 7
SP - 28151
EP - 28159
JO - ONCOTARGET
JF - ONCOTARGET
SN - 1949-2553
IS - 19
ER -
